New transcription factors and their role in diabetes and therapy /

This book contains contributions from some of the most eminent experts in the fields of genetics, biochemistry, and pathophysiology of diabetes. Through specific examples, with broad applications, this book provides a comprehensive look at how transcription factors may underline the pathogenetic mec...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Άλλοι συγγραφείς: Friedman, Jacob E.
Μορφή: Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Amsterdam ; Boston : Elsevier, 2006.
Έκδοση:1st ed.
Σειρά:Advances in molecular and cellular endocrinology ; v. 5.
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 06805nam a2200637 4500
001 ocn162130225
003 OCoLC
005 20180501121912.0
006 m o d
007 cr cn|||||||||
008 070802s2006 ne a ob 001 0 eng d
040 |a OPELS  |b eng  |e pn  |c OPELS  |d BAKER  |d OPELS  |d OCLCQ  |d N$T  |d E7B  |d NRU  |d OCLCQ  |d REDDC  |d OCLCQ  |d TULIB  |d OCLCO  |d OCLCQ  |d OPELS  |d NLGGC  |d CHVBK  |d YDXCP  |d IDEBK  |d UKDOC  |d OCLCQ  |d OHS  |d DEBSZ  |d AGLDB  |d OCLCQ  |d CASUM  |d JBG  |d OCLCO  |d OCLCA  |d OCLCF  |d GrThAP 
019 |a 123453129  |a 154703295  |a 647616745  |a 742299912  |a 779917399  |a 814467983  |a 823136993  |a 823857107  |a 823927179  |a 824116818  |a 824168594  |a 1011183853  |a 1024274974 
020 |a 9780444511584 
020 |a 044451158X 
020 |a 9780080463551 
020 |a 008046355X 
035 |a (OCoLC)162130225  |z (OCoLC)123453129  |z (OCoLC)154703295  |z (OCoLC)647616745  |z (OCoLC)742299912  |z (OCoLC)779917399  |z (OCoLC)814467983  |z (OCoLC)823136993  |z (OCoLC)823857107  |z (OCoLC)823927179  |z (OCoLC)824116818  |z (OCoLC)824168594  |z (OCoLC)1011183853  |z (OCoLC)1024274974 
050 4 |a QP187.3.M64  |b A38 v.5eb 
060 4 |a W1  |b AD6823 v.5 2006 
060 4 |a WK 810  |b N5329 2006 
072 7 |a HEA  |x 039050  |2 bisacsh 
072 7 |a K  |2 bicssc 
082 0 4 |a 616.46207  |2 22 
049 |a TEFA 
245 0 0 |a New transcription factors and their role in diabetes and therapy /  |c editor, Jacob E. Friedman. 
250 |a 1st ed. 
260 |a Amsterdam ;  |a Boston :  |b Elsevier,  |c 2006. 
300 |a 1 online resource (xii, 309 pages) :  |b illustrations. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Advances in molecular and cellular endocrinology ;  |v v. 5 
520 |a This book contains contributions from some of the most eminent experts in the fields of genetics, biochemistry, and pathophysiology of diabetes. Through specific examples, with broad applications, this book provides a comprehensive look at how transcription factors may underline the pathogenetic mechanisms of diabetes and obesity. Volume 5 provides an overview of the status of the field, while also providing valuable information of practical utility to those who do not necessarily work in this field. The integration of basic biology with physiologically and clinically relevant proteins should provide the reader with a theoretical background to understanding the strategies for new potential therapeutic targets and their application to disease. *Applies molecular biology to transcriptional regulation of metabolism and obesity *Underscores the clinical relevance of transcription factors *Provides a valuable overview of the current status of the field. 
505 0 |a 1. PPARs as therapeutic targets for treating diabetes and insulin resistance -- 2. Genetic regulators of human obesity and diabetes -- 3. NF-kb, insulin resistance and the actions of salicylates -- 4. Wnt signaling and C/EBPs role in adipogenesis -- 5. Regulation of hepatic gluconeogenesis C/EPBs -- 6. Forkhead proteins and regulation of hepatic gene expression -- 7. Control of mitochondrial biogenesis through PGC-1 -- 8. Regulation of PGC-1 in humans in insulin resistance and diabetes: Functional implications -- 9. FOXC2 controls resistance to obesity and Type II diabetes -- 10. SREB-1C regulation of nutrient homeostasis and lipid accumulation -- 11. GATA proteins as molecular gatekeeprs of the adipocyte -- 12. Diabetes regulation of gene expression by CREB -- 13. Molecular etiologies of MODY and other early-onset forms of diabetes -- 14. Liver X receptors as potential drug targets for Diabetes and its disorders -- 15. The potential therapeutic use of PPAR beta/delta agonists in lipid and glucose homeostasis -- 16. Influences of new PPAR insulin sensitizers on the metabolic syndrome in Rhesus Monkeys -- 17. PPARgamma and metabolism: Insights from the study of human genetic variants. 
505 0 |a Transcription factor genes in type 2 diabetes / by M.N. Weedon, A.T. Hattersley & T.M. Frayling -- PPAR[gamma], a key therapeutic target in the metabolic syndrome-unique insights derived from the study of human genetic variants / by C.S. Mitchell & M. Gurnell -- PPAR[delta]: emerging therapeutic potential of novel agonists in lipid and glucose homeostasis / by U. Dressel & G.E.O. Muscat -- Liver X receptors as potential drug targets for diabetes and its disorders / by K.R. Steffenson -- SREBP-lc regulation of nutrient homeostasis and lipid accumulation / by P. Ferré [and others] -- The adipocyte and adipose tissue as endocrine organs: impact on the insulin resistance phenotype / by R.R. Henry [and others] -- FOXC2 in the adipocyte / by S. Enerbäck -- Regulation of adipocyte differentiation and metabolism by Wnt signaling and C/EBP transcription factors / by I. Gerin, H.D. Cha & O.A. MacDougald -- GATA proteins as molecular gatekeepers of adipogenesis / by J. Tsai, Q. Tong & G.S. Hotamisligil -- Forkhead proteins and the regulation of hepatic gene expression / by A. Barthel, S. Herzig & D. Schmoll -- Disruption of CREB regulated of gene expression in diabetes / by J.E.B. Reusch, P.A. Watson & S. Pugazhenthi -- Regulation of PGC-1 in humans with insulin resistance and type 2 diabetes: functional implications / by J. Pihlajamäki & M.E. Patti -- Hepatic CCAAT/enhancer binding protein [beta] (C/EBP[beta]): engineer of diabetes, obesity, and inflammatory disease processes / by J.M. Schroeder-Gloeckler, S.M. Rahman & J.E. Friedman -- Insulin resistance, inflammation, and the IKK/I[kappa]B/NF-[kappa]B pathway by B.A. Bhatt & R.M. O'Doherty. 
504 |a Includes bibliographical references and index. 
588 0 |a Print version record. 
650 0 |a Transcription factors. 
650 0 |a Diabetes  |x Genetic factors. 
650 0 |a Diabetes  |x Pathophysiology. 
650 6 |a Diabète  |x Physiopathologie. 
650 6 |a Facteurs de transcription. 
650 6 |a Obésité  |x Physiopathologie. 
650 7 |a HEALTH & FITNESS  |x Diseases  |x Diabetes.  |2 bisacsh 
650 1 2 |a Diabetes Mellitus, Type 2.  |0 (DNLM)D003924 
650 1 2 |a Transcription Factors.  |0 (DNLM)D014157 
650 2 2 |a Diabetes Mellitus, Type 2  |x genetics.  |0 (DNLM)D003924Q000235 
650 2 2 |a Diabetes Mellitus, Type 2  |x physiopathology.  |0 (DNLM)D003924Q000503 
650 7 |a Diabetes  |x Pathophysiology.  |2 fast  |0 (OCoLC)fst00892180 
650 7 |a Transcription factors.  |2 fast  |0 (OCoLC)fst01154564 
655 4 |a Electronic books. 
700 1 |a Friedman, Jacob E. 
776 0 8 |i Print version:  |t New transcription factors and their role in diabetes and therapy.  |b 1st ed.  |d Amsterdam ; Boston : Elsevier, 2006  |z 044451158X  |z 9780444511584  |w (OCoLC)84712688 
830 0 |a Advances in molecular and cellular endocrinology ;  |v v. 5. 
856 4 0 |u https://www.sciencedirect.com/science/bookseries/15692566/5  |z Full Text via HEAL-Link